TY - JOUR
T1 - Masaoka-koga and tnm staging system in thymic epithelial tumors
T2 - Prognostic comparison and the role of the number of involved structures
AU - Chiappetta, Marco
AU - Lococo, Filippo
AU - Pogliani, Luca
AU - Sperduti, Isabella
AU - Tabacco, Diomira
AU - Bria, Emilio
AU - D’argento, Ettore
AU - Massaccesi, Mariangela
AU - Boldrini, Luca
AU - Meacci, Elisa
AU - Porziella, Venanzio
AU - Nachira, Dania
AU - Congedo, Maria Teresa
AU - Margaritora, Stefano
N1 - Funding Information:
We would like to thank Franziska M. Lohmeyer, Fondazione Policlinico Uni-versitario A. Gemelli IRCCS, for her support revising our manuscript.
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/11/1
Y1 - 2021/11/1
N2 - Background: The aim of this study was to evaluate the Masaoka–Koga and the tumor node metastases (TNM) staging system in thymic epithelial tumors (TET) considering possible improvements. Methods: We reviewed the data of 379 patients who underwent surgical resection for TET from 1 January 1985 to 1 January 2018, collecting and classifying the pathological report according to the Masaoka–Koga and the TMN system. The number of involved organs was also considered as a possible prognostic factor and integrated in the two staging systems to verify its impact. Results: Considering the Masaoka–Koga system, 5-and 10-year overall survival (5–10YOS) was 96.4% and 88.9% in stage I, 95% and 89.5% in stage II and 85.4% and 72.8% in stage III (p = 0.01), with overlapping in stage I and stage II curves. Considering the TNM system, 5–10YOS was 95.5% and 88.8% in T1, 84.8% and 70.7% in T2 and 88% and 76.3% in T3 (p = 0.02), with overlapping T2– T3 curves. Including the number of involved structures, in Masaoka–Koga stage III, patients with singular involved organs had a 100% and 76.6% vs. 87.7% 5–10YOS, which was 76.6% in patients with multiple organ infiltration. Considering the TNM, T3 patients with singular involved structures presented a 5–10YOS of 100% vs. 62.5% and 37.5% in patients with multiple organ involvement (p = 0.07). Conclusion: The two staging systems present limitations due to overlapping curves in early Masaoka–Koga stages and in advanced T stages for TNM. The addition of the number of involved organs seems to be a promising factor for the prognosis stratification in these patients.
AB - Background: The aim of this study was to evaluate the Masaoka–Koga and the tumor node metastases (TNM) staging system in thymic epithelial tumors (TET) considering possible improvements. Methods: We reviewed the data of 379 patients who underwent surgical resection for TET from 1 January 1985 to 1 January 2018, collecting and classifying the pathological report according to the Masaoka–Koga and the TMN system. The number of involved organs was also considered as a possible prognostic factor and integrated in the two staging systems to verify its impact. Results: Considering the Masaoka–Koga system, 5-and 10-year overall survival (5–10YOS) was 96.4% and 88.9% in stage I, 95% and 89.5% in stage II and 85.4% and 72.8% in stage III (p = 0.01), with overlapping in stage I and stage II curves. Considering the TNM system, 5–10YOS was 95.5% and 88.8% in T1, 84.8% and 70.7% in T2 and 88% and 76.3% in T3 (p = 0.02), with overlapping T2– T3 curves. Including the number of involved structures, in Masaoka–Koga stage III, patients with singular involved organs had a 100% and 76.6% vs. 87.7% 5–10YOS, which was 76.6% in patients with multiple organ infiltration. Considering the TNM, T3 patients with singular involved structures presented a 5–10YOS of 100% vs. 62.5% and 37.5% in patients with multiple organ involvement (p = 0.07). Conclusion: The two staging systems present limitations due to overlapping curves in early Masaoka–Koga stages and in advanced T stages for TNM. The addition of the number of involved organs seems to be a promising factor for the prognosis stratification in these patients.
KW - Masaoka–Koga
KW - Surgery
KW - Thymic carcinoma
KW - Thymoma
KW - TNM
UR - http://www.scopus.com/inward/record.url?scp=85117331637&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85117331637&partnerID=8YFLogxK
U2 - 10.3390/cancers13215254
DO - 10.3390/cancers13215254
M3 - Article
AN - SCOPUS:85117331637
VL - 13
JO - Cancers
JF - Cancers
SN - 2072-6694
IS - 21
M1 - 5254
ER -